Abstract
BackgroundAccurate assessment of minimal residual disease (MRD) in acute lymphoblastic leukemia (ALL) patients after initial chemotherapy is essential to evaluate the efficacy of therapeutic regimens. Wilms tumor 1 (WT1) is...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have